Mironid

Molecules to modulate the activity of phosphodiesterase 4 (PDE4) enzymes to treat inflammatory disease and degenerative kidney disease.

placeGlasgow, Scotland, United Kingdom calendar_todayFounded 2015 groups12 employees language mironid.com

Registered entities

Social engagement

Social engagement: 1.2K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

8 investors on record; lead investors include Roche, Sofinnova Partners, BioGeneration Ventures, European Investment Fund.

Investor typeCountShare
Venture capital338%
Private equity225%
Other / undisclosed338%

Recent activity

17 Jun 2026
Event
Creative Disruption Forum: The Latest Dealmaking and Investment and Creative Disruption Forum: Modern Drug Discovery
16 Feb 2026
Event
Ace Drug Discovery Summit
30 Oct 2025
Event
BioEurope conference
Coming soon